pre-IPO PHARMA

COMPANY OVERVIEW

BlackThorn Therapeutics is a computational sciences company with capabilities to develop proprietary therapeutics focused on neurobehavioral disorders. BlackThorn has pioneered the development of a computational psychiatry platform to advance its robust pipeline of novel therapeutics. The company uses data-driven approaches to solve the patient selection problem to create treatments that improve patient outcomes.


LOCATION

  • San Francisco, CA, USA

  • THERAPEUTIC AREAS

  • Neurological Disorders

  • WEBSITE

    https://www.blackthornrx.com


    CAREER WEBSITE

    https://www.blackthornrx.com/career-in-neurobehavioral-science/


    SOCIAL MEDIA


    INVESTORS

    alexandria-venture-investments altitude-life-science-ventures arch-venture-partners biomatics-capital gv jjdc mercury-fund polaris-partners premier-partners vertex-ventures-hc


    PRESS RELEASES


    Jan 23, 2020

    BlackThorn Therapeutics Advances Phase 2 Clinical Development for Selective KOR Antagonist, BTRX-140, in Neuropsychiatric Disorders


    Dec 11, 2019

    BlackThorn Therapeutics Reports Data Supporting Phase 2 Development of KOR Antagonist, BTRX-335140, in Depression and Other CNS Disorders


    Oct 23, 2019

    BlackThorn Therapeutics Reports New Insights into Neurobehavioral Disorders at the 49th Annual Meeting of the Society for Neuroscience


    Oct 21, 2019

    BlackThorn Therapeutics Appoints William J. Martin, Ph.D., as Chief Executive Officer to Lead Next Stage of Growth


    Sep 9, 2019

    BlackThorn Therapeutics Appoints Healthcare Technology Innovator, Monique Levy, as Chief Strategy Officer


    For More Press Releases


    Google Analytics Alternative